

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2006 (08.09.2006)

PCT

(10) International Publication Number
WO 2006/094192 A3

(51) International Patent Classification:
A61K 39/395 (2006.01) C12N 15/13 (2006.01)

(21) International Application Number:
PCT/US2006/007598

(22) International Filing Date: 3 March 2006 (03.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/657,695 3 March 2005 (03.03.2005) US

(71) Applicant (for all designated States except US): IMMUNOMEDICS, INC. [US/US]; 300 American Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GOLDENBERG, David, M. [US/US]; 1 Charolais Farm Road, Mendham, NJ 07945 (US). HANSEN, Hans, J. [US/US]; 6014 Angler Drive, Picayune, MS 39466 (US). QU, Zhengxing [US/US]; 15 Sycamore Way, Warren, NJ 07950 (US). CHANG, Chen-Hsing [US/US]; 349 French Circle, Downingtown, PA 19335 (US).

(74) Agents: HANSON, Roberta, J. et al.; Faegre & Benson LLP, Customer No. 35657, 2200 Wells Fargo Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 November 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2006/094192 A3

(54) Title: HUMANIZED L243 ANTIBODIES

(57) Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US06/07598

A. CLASSIFICATION OF SUBJECT MATTER
 IPC: **A61K 39/395(2006.01);C12N 15/13(2006.01)**

 USPC: **530/387.3;424/133.1**
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 530/387.3; 424/133.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet


C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LUND, J. et al. Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcγ receptor I. Eur. J. Biochem. December 2000. Vol. 267, No. 24, pages 7246-7257, see entire document.	1-3

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 27 June 2006 (27.06.2006)	Date of mailing of the international search report 07 SEP 2006
--	---

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer F. Pierre VanderVegt Telephone No. 571-272-1600 
---	--

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US06/07598

Continuation of B. FIELDS SEARCHED Item 3:
EAST, Medline, Embase, Scisearch

TERMS: L243, humanized, monoclonal, antibody, HLA-DR